Immutep Limited, a biotechnology company, is dedicated to the research and development of pharmaceutical candidates. The company is headquartered in Sydney, Australia. Show more

AUSTRALIA SQUARE, SYDNEY, NSW, AUSTRALIA, 2000, L 12 95 Pitt St, Sydney, NSW, 2000, USA

https://www.immutep.com

BIOTECHNOLOGY

HEALTHCARE

Start AI Chat

Market Cap

48.79M

52 Wk Range

$0.29 - $3.32

Previous Close

$0.37

Open

$0.34

Volume

509,330

Day Range

$0.32 - $0.35

Enterprise Value

10.52M

Cash

68.88M

Avg Qtr Burn

-29.15M

Insider Ownership

0.01%

Institutional Own.

1.13%

Qtr Updated

06/30/26

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) Details Metastatic breast cancer	Phase 2/3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod Alpha + Pembrolizumab Details Soft tissue sarcoma	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Neoadjuvant Eftilagimod Alfa (Efti) +/- SoC Details Early-stage HR+/HER2-negative breast cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMP761 (LAG-3 agonist) Details Autoimmune disease	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod Alpha + KEYTRUDA and chemotherapy Details Non-small cell lung carcinoma (1L NSCLC)	Phase 1 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod Alpha (LAG-3lg or IMP321) (APC activating Soluble LAG-3 Protein) and avelumab Details Solid tumor/s, Cancer, Urothelial cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod alfa (efti) + Keytruda Details Non-small cell lung carcinoma (1L NSCLC)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Eftilagimod Alpha (LAG-3lg or IMP321) + Keytruda Details Head and neck squamous cell carcinoma (1L HNSCC)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
IMP761 (Agonist AB) Details COVID-19	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.